Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of CB1 Antagonist ANEB-001 in Healthy Occasional Cannabis Users in a THC Challenge Test.

NCT05282797 is registered in ClinicalTrials.gov with Anebulo Pharmaceuticals as lead sponsor.

NCT NCT05282797
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05282797 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Double-blind, Placebo-controlled Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single Oral Doses of CB1 Antagonist ANEB-001 in Healthy Occasional Cannabis Users in a THC Challenge Test.
Lead sponsor
Anebulo Pharmaceuticals
Phase
Phase 2
Overall status
Completed
Start date
December 15, 2021
Completion date
August 26, 2023
Enrollment
154 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

acute cannabinoid intoxication